Dyne says Duchenne drug succeeds in pivotal study, heads to FDA for approval

Dyne Therapeutics announced Monday that its Duchenne muscular dystrophy drug hit the primary endpoint in a key study and plans to take the experimental treatment to the FDA for accelerated approval. Dyne is one of ...